drugset
drugset / Trial / NCT00519298

Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects

NCT00519298 ↗

Phase 1 Completed 25 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedCrossoverDouble-blind

Summary

Primary: To evaluate the pharmacologic effect of single doses of SAM-531 on sleep EEG in healthy subjects.

Timeline

Start
2007-10
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject CERLAPIRDINE Small molecule 1 mg —
Subject CERLAPIRDINE Small molecule 3 mg —
Subject CERLAPIRDINE Small molecule 10 mg —
Comparator Donepezil Small molecule 5 mg —

Indications

No indication recorded.